US 12,479,847 B2
Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2
Nathanael S. Gray, Boston, MA (US); John Hatcher, Boston, MA (US); Jieun Choi, Seoul (KR); Sun-Hwa Lee, Daegu (KR); Hwangeun Choi, Seoul (KR); Eunhwa Ko, Incheon (KR); Yeonsil Kim, Incheon (KR); Daekwon Kim, Daegu (KR); Namdoo Kim, Incheon (KR); and Jungbeom Son, Incheon (KR)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US); and VORONOI INC., Incheon (KR)
Appl. No. 17/610,066
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US); and VORONOI INC., Incheon (KR)
PCT Filed May 15, 2020, PCT No. PCT/US2020/033056
§ 371(c)(1), (2) Date Nov. 9, 2021,
PCT Pub. No. WO2020/232332, PCT Pub. Date Nov. 19, 2020.
Claims priority of provisional application 62/848,920, filed on May 16, 2019.
Prior Publication US 2022/0204515 A1, Jun. 30, 2022
Int. Cl. C07D 487/04 (2006.01); A61P 25/28 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 25/28 (2018.01)] 11 Claims
 
1. A compound having a structure of formula (I):

OG Complex Work Unit Chemistry
wherein
X1 is N or CR1, wherein R1 is H, halogen, CN, or CF3;
X2 is CH or N, provided that only one of X1 and X2 is N;
R2 is

OG Complex Work Unit Chemistry
R3 and R4, together with the atoms to which they are attached, form a 1,4-dioxenyl group, 1,3-dioxenyl group, or a 2,3-dihydrofuranyl group; and
R5 is C(O)R6, S(O)2R6 or

OG Complex Work Unit Chemistry
wherein
R6 is methyl,

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof.